Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Pulmonary Function Tests

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Smoking-Related Clinical and Molecular Abnormalities in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension.

Pulmonary circulation·2026

Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026

Same author

Metered cryospray in patients with chronic bronchitis: a mechanistic randomised controlled study.

Thorax·2026

Same author

Mycophenolate and Azathioprine in Fibrotic Interstitial Lung Disease.

American journal of respiratory and critical care medicine·2026

Same author

Longitudinal Mediastinal Lymph Node Dynamics Associate with Mortality and Fibrosis Progression in Fibrotic ILD.

Chest·2026

Same author

Two Blood-based Endotypes Reveal Divergent Clinical Outcomes of Fibrotic Hypersensitivity Pneumonitis.

medRxiv : the preprint server for health sciences·2026

Search research articles

Related Experiment Video

Updated: Oct 14, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Lung function trajectory in progressive fibrosing interstitial lung disease.

Justin M Oldham^1,2, Cathryn T Lee^3,2, Zhe Wu^4,5

¹Division of Pulmonary, Critical Care and Sleep Medicine, University of California at Davis, Sacramento, CA, USA joldham@ucdavis.edu.

The European Respiratory Journal

|November 5, 2021

Summary

Identifying progressive fibrosing interstitial lung disease (PF-ILD) criteria that predict forced vital capacity (FVC) decline is crucial. The study found that specific PF-ILD criteria, particularly radiological progression, significantly impact FVC change, varying by interstitial lung disease (ILD) subtype.

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Related Experiment Videos

Last Updated: Oct 14, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Area of Science:

Pulmonary Medicine
Clinical Research
Interstitial Lung Disease

Background:

Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD) are linked to mortality.
Lung function trajectory after meeting PF-ILD criteria is largely unknown.
Predicting forced vital capacity (FVC) change is vital for clinical trial design.

Purpose of the Study:

To evaluate how individual PF-ILD criteria predict subsequent FVC change.
To determine if PF-ILD criteria can be refined for better clinical trial design.
To assess the influence of ILD subtype on FVC trajectory after PF-ILD diagnosis.

Main Methods:

Retrospective, multicentre longitudinal cohort analysis of 1227 patients.
Included patients with fibrotic connective tissue disease-associated ILD (CTD-ILD), chronic hypersensitivity pneumonitis, and idiopathic interstitial pneumonia.
Joint modelling used to estimate 1-year FVC change after meeting PF-ILD criteria.

Main Results:

Six of nine PF-ILD criteria were associated with differential 1-year FVC change.
Radiological progression of fibrosis showed the largest FVC decline.
FVC change varied significantly by ILD subtype, with CTD-ILD showing less change.

Conclusions:

Near-term FVC change after meeting PF-ILD criteria is heterogeneous.
ILD subtype significantly influences FVC trajectory and should be considered when applying PF-ILD criteria.
Findings can inform future clinical trial design for interstitial lung diseases.